Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA-HLA II
- Development stage
- Unknown
- Lead developer
- Labo'Life
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Sublingual
01
Overview
SNA-HLA II is a micro-immunotherapy medicine developed by Labo'Life Belgium, specifically designed for the management of Herpes Simplex Virus (HSV) infections, including orofacial herpes. It consists of specific nucleic acids (SNA) that are highly diluted and intended to modulate the immune system's response to the virus. The mechanism of action involves the targeted regulation of Human Leukocyte Antigen (HLA) Class II expression, which plays a critical role in the presentation of viral antigens to the immune system. By influencing these pathways, SNA-HLA II aims to restore immune balance, potentially reducing the frequency of viral reactivations and supporting the host's natural defense mechanisms. It is typically administered sublingually in the form of globules, allowing for absorption through the oral mucosa.
- Brand names
- SNA-HLA II
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on SNA-HLA II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA-HLA II.